Pulmonx Co. (NASDAQ:LUNG) Receives $14.17 Consensus PT from Analysts
Pulmonx Co. (NASDAQ:LUNG – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages […]
More Stories
Global X Clean Tech ETF (NASDAQ:CTEC) Sees Large Decrease in Short Interest
Global X Clean Tech ETF (NASDAQ:CTEC – Get Free Report) saw a significant decline in short interest in the month...
International Isotopes Inc. (OTCMKTS:INIS) Short Interest Down 94.5% in December
International Isotopes Inc. (OTCMKTS:INIS – Get Free Report) was the target of a significant drop in short interest in December....
Cochlear Limited (OTCMKTS:CHEOY) Sees Large Decrease in Short Interest
Cochlear Limited (OTCMKTS:CHEOY – Get Free Report) was the recipient of a significant drop in short interest during the month...
Insider Buying: Crescita Therapeutics Inc. (TSE:CTX) Director Acquires 86,000 Shares of Stock
Crescita Therapeutics Inc. (TSE:CTX – Get Free Report) Director Jose Darocha bought 86,000 shares of the company’s stock in a...
Presidio Property Trust, Inc. (NASDAQ:SQFT) Short Interest Update
Presidio Property Trust, Inc. (NASDAQ:SQFT – Get Free Report) was the recipient of a significant growth in short interest in...
Short Interest in iShares ESG MSCI USA Leaders ETF (NASDAQ:SUSL) Rises By 353.3%
iShares ESG MSCI USA Leaders ETF (NASDAQ:SUSL – Get Free Report) saw a significant increase in short interest in the...